A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 7, 2021

Primary Completion Date

February 17, 2022

Study Completion Date

February 17, 2022

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

PF-06882961

Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)

DRUG

Placebo

3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)

Trial Locations (1)

Peking University Third Hospital, Beijing